Concepedia

Accelerated Dose Escalation

Accelerated Dose Escalation is a dose escalation design in early-phase clinical trials that belongs to the class of model-based methods and is distinguished by its use of predefined, rapidly increasing dose levels with limited safety monitoring at each level to expedite identification of the maximum tolerated dose.

235

Publications

19.8K

Citations

2.2K

Authors

633

Institutions

Publications per year

2017–2026

81

Parents

Publications

235

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

, , +13

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 1K citations

, , +15

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer

Michael J. Zeléfsky, StevenA Leibel, PaulB Gaudin et al. · International Journal of Radiation Oncology*Biology*Physics · 1998 · 926 citations

, , +16

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Richard Simon, Larry Rubinstein, Susan G. Arbuck et al. · JNCI Journal of the National Cancer Institute · 1997 · 640 citations · Full text

, , +17

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú et al. · Cancer Discovery · 2017 · 418 citations

, , +14

1–5 of 235

Authors

2.2K

  1. MJ
    Michael J. Zeléfsky

    Memorial Sloan Kettering Cancer Center, United States

    8 publications · 1.6K citations

    8

    h-index

  2. HA
    Howard A. Burris

    Sarah Cannon, United States

    8 publications · 536 citations

    8

    h-index

  3. AW
    Anthony W. Tolcher

    South Texas Accelerated Research Therapeutics, United States

    7 publications · 1.6K citations

    7

    h-index

  4. MR
    Manish R. Patel

    Sarah Cannon, United States

    5 publications · 742 citations

    5

    h-index

  5. ZF
    Zvi Fuks

    Memorial Sloan Kettering Cancer Center, United States

    5 publications · 1.2K citations

    5

    h-index

1–5 of 2.2K

Institutions

633

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    20 h-index

    128 publications

    10.8K citations

  2. Memorial Sloan Kettering Cancer Center

    New York, United States

    18 h-index

    118 publications

    18.8K citations

  3. Sarah Cannon

    Nashville, United States

    15 h-index

    49 publications

    3K citations

  4. Massachusetts General Hospital

    Boston, United States

    15 h-index

    60 publications

    6.8K citations

  5. Dana-Farber Cancer Institute

    Boston, United States

    15 h-index

    64 publications

    6.2K citations

  6. Tennessee Oncology

    Nashville, United States

    11 h-index

    15 publications

    1.3K citations

  7. Princess Margaret Cancer Centre

    Toronto, Canada

    8 h-index

    37 publications

    1.3K citations

  8. University of Wisconsin–Madison

    Madison, United States

    8 h-index

    34 publications

    1.5K citations

1–8 of 633

Venues

  1. 30

    h-index

  2. Journal of Clinical Oncology

    43 publications · 2.9K citations

    22

    h-index

  3. Blood

    22 publications · 871 citations

    16

    h-index

  4. Radiotherapy and Oncology

    15 publications · 738 citations

    15

    h-index

  5. Clinical Cancer Research

    9 publications · 1.1K citations

    9

    h-index

1–5